Determine which patients with cancer should be or could be treated with a direct oral anticoagulant (DOAC) and the factors involved in making benefit-to-risk decisions in unclear situations
Describe the similarities and differences between DOACs, including the clinical data in patients with cancer
Apply recent data evaluating the use of DOACs for the prevention and treatment of cancer-associated venous thromboembolism
